Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine |
| |
Authors: | Weixu Feng,Yunru Xiang,Lianpeng Wu,Zhuo Chen,Qingfeng Li,Jun Chen,Yanru Guo,Dandan Xia,Na Chen,Lifang Zhang,Shanli Zhu,Kong‐ Nan Zhao |
| |
Affiliation: | 1. School of Basic Medical Science, Wenzhou Medical University, Wenzhou China ; 2. Department of Laboratory Medicine, The Sixth People Hospital of Wenzhou, Wenzhou China ; 3. Department of Obstetrics and Gynaecology, The Second Affiliated Hospital and Yuyin Children Hospital of Wenzhou Medical University, Wenzhou China ; 4. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia Queensland, Australia |
| |
Abstract: | BackgroundSARS‐CoV‐2 has spread worldwide causing more than 400 million people with virus infections since early 2020. Currently, the existing vaccines targeting the spike glycoprotein (S protein) of SARS‐CoV‐2 are facing great challenge from the infection of SARS‐CoV‐2 virus and its multiple S protein variants. Thus, we need to develop a new generation of vaccines to prevent infection of the SARS‐CoV‐2 variants. Compared with the S protein, the nucleocapsid protein (N protein) of SARS‐CoV‐2 is more conservative and less mutations, which also plays a vital role in viral infection. Therefore, the N protein may have the great potential for developing new vaccines.MethodsThe N protein of SARS‐CoV‐2 was recombinantly expressed and purified in Escherichia coli. Western Blot and ELISA assays were used to demonstrate the immunoreactivity of the recombinant N protein with the serum of 22 COVID‐19 patients. We investigated further the response of the specific serum antibodies and cytokine production in BALB/c mice immunized with recombinant N protein by Western Blot and ELISA.ResultsThe N protein had good immunoreactivity and the production of IgG antibody against N protein in COVID‐19 patients was tightly correlated with disease severity. Furthermore, the N protein was used to immunize BALB/c mice to have elicited strong immune responses. Not only high levels of IgG antibody, but also cytokine‐IFN‐γ were produced in the N protein‐immunized mice. Importantly, the N protein immunization induced a high level of IgM antibody produced in the mice.ConclusionSARS‐CoV‐2 N protein shows a great big bundle of potentiality for developing a new generation of vaccines in fighting infection of SARS‐CoV‐2 and its variants. |
| |
Keywords: | antibody, immune response, nucleocapsid protein, SARS‐ CoV‐ 2, vaccine |
|
|